Immunophotonics, Inc. is attending the BioGenerator Startup Connect event during the networking breaks
Published
Signal category
Presence & Recognition
Quote
“feel free to reach out during the networking breaks or stop by our table”
— Robert Arch|Immunophotonics, Inc. team
Company
Immunophotonics, Inc.
Interventional Immuno-Oncology
- Industry
- Pharmaceutical Manufacturing
- Location
- St. Louis, US
- Company size
- 19 employees
Immunophotonics is a privately owned clinical stage biotech that has discovered a novel and simple approach to achieve patient-specific anticancer immunity. The company is currently developing its first asset, the immune-modulating proprietary carbohydrate polymer IP-001 for the treatment of solid tumor cancers. IP-001 has unique physio-chemical and immunological properties that allows it to ignite a systemically active cancer immunotherapy from a routine tumor ablation; a minimal invasive intervention that destroys tumors and in doing so liberates tumor antigens. IP-001 enhances interactions of tumor antigens with the immune system, improves the motility of tumor infiltrating T cells, promotes their surveillance of tumor tissue and can generate long-term protective immunity.
Founded 2012